Compare Wockhardt with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs STRIDES PHARMA SCIENCE - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT STRIDES PHARMA SCIENCE WOCKHARDT/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -22.2 14.8 - View Chart
P/BV x 1.2 0.9 133.7% View Chart
Dividend Yield % 0.0 0.6 0.6%  

Financials

 WOCKHARDT   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
WOCKHARDT/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,0121,147 88.2%   
Low Rs532642 82.8%   
Sales per share (Unadj.) Rs355.9317.2 112.2%  
Earnings per share (Unadj.) Rs-60.37.8 -768.4%  
Cash flow per share (Unadj.) Rs-46.825.1 -186.6%  
Dividends per share (Unadj.) Rs0.012.00 0.5%  
Dividend yield (eoy) %00.2 0.6%  
Book value per share (Unadj.) Rs257.8274.3 94.0%  
Shares outstanding (eoy) m110.6389.50 123.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.8 76.9%   
Avg P/E ratio x-12.8114.0 -11.2%  
P/CF ratio (eoy) x-16.535.7 -46.2%  
Price / Book Value ratio x3.03.3 91.8%  
Dividend payout %025.5 -0.1%   
Avg Mkt Cap Rs m85,37980,058 106.6%   
No. of employees `0006.32.5 249.5%   
Total wages/salary Rs m9,3714,341 215.9%   
Avg. sales/employee Rs Th6,295.011,325.8 55.6%   
Avg. wages/employee Rs Th1,498.31,731.4 86.5%   
Avg. net profit/employee Rs Th-1,066.3280.1 -380.7%   
INCOME DATA
Net Sales Rs m39,36928,394 138.7%  
Other income Rs m1,202941 127.8%   
Total revenues Rs m40,57129,334 138.3%   
Gross profit Rs m183,965 0.5%  
Depreciation Rs m1,4951,540 97.1%   
Interest Rs m2,5551,962 130.2%   
Profit before tax Rs m-2,8301,403 -201.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-3,582-436 821.9%   
Tax Rs m25797 264.1%   
Profit after tax Rs m-6,669702 -949.8%  
Gross profit margin %014.0 0.3%  
Effective tax rate %-9.16.9 -131.0%   
Net profit margin %-16.92.5 -685.0%  
BALANCE SHEET DATA
Current assets Rs m33,79624,836 136.1%   
Current liabilities Rs m26,91718,993 141.7%   
Net working cap to sales %17.520.6 84.9%  
Current ratio x1.31.3 96.0%  
Inventory Days Days7971 111.8%  
Debtors Days Days89113 78.7%  
Net fixed assets Rs m39,66434,289 115.7%   
Share capital Rs m553895 61.8%   
"Free" reserves Rs m27,96823,651 118.3%   
Net worth Rs m28,52224,546 116.2%   
Long term debt Rs m21,73115,513 140.1%   
Total assets Rs m81,62065,437 124.7%  
Interest coverage x-0.11.7 -6.3%   
Debt to equity ratio x0.80.6 120.6%  
Sales to assets ratio x0.50.4 111.2%   
Return on assets %-5.04.1 -123.8%  
Return on equity %-23.42.9 -817.4%  
Return on capital %-7.76.9 -111.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80715,697 62.5%   
Fx outflow Rs m1,789735 243.2%   
Net fx Rs m8,01914,962 53.6%   
CASH FLOW
From Operations Rs m6841,871 36.6%  
From Investments Rs m6,3025,826 108.2%  
From Financial Activity Rs m-7,695-10,157 75.8%  
Net Cashflow Rs m-664-2,615 25.4%  

Share Holding

Indian Promoters % 74.5 27.7 269.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 37.8 6.1%  
FIIs % 7.7 8.6 89.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 25.9 59.5%  
Shareholders   67,757 56,241 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  UNICHEM LAB  

Compare WOCKHARDT With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Jumps 1,921 Points, FM's Tax Relief, and Top Cues in Focus Today(Pre-Open)

Share markets in India jumped sharply on Friday after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Sep 20, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS